Low-dose dexmedetomidine adjunct to ciprofol for gastrointestinal endoscopy: a retrospective study of relative MAP reduction and rescue interventions

Objective To examine the association of low-dose dexmedetomidine (0.3 μg/kg) added to ciprofol sedation with a patient-level mean arterial pressure (MAP) reduction of at least 20% from baseline, recorded rescue interventions, and early recovery during gastrointestinal endoscopy. Methods This single-center, retrospective, non-randomized comparative study included 100 adults (dexmedetomidine–ciprofol, n = 50; ciprofol alone, n = 50). No upper age limit was applied. In the adjunctive group, dexmedetomidine 0.3 μg/kg was administered intravenously before ciprofol; both groups received ciprofol titrated to clinical response. The primary outcome was an individual MAP decrease of at least 20% from the pre-sedation baseline, defined in the retrospective analysis plan before patient-level outcome derivation and between-group comparisons. Secondary outcomes included recorded rescue intervention, ciprofol dose, awakening time, intraoperative cardiorespiratory measures, bradycardia, hypoxemia, and other documented adverse reactions. Exploratory adjusted analyses supplemented unadjusted comparisons. Results The incidence of a MAP reduction of at least 20% was 16.0% vs. 36.0% [8/50 vs. 18/50; odds ratio [OR] 0.34, 95% confidence interval [CI]: 0.13–0.88; P = 0.039] in the dexmedetomidine-ciprofol and ciprofol-only groups, respectively. Recorded rescue interventions occurred in 20.0% vs. 40.0% (10/50 vs. 20/50; OR: 0.38, 95% CI: 0.15–0.92; P = 0.049). Mean lowest intraoperative MAP and mean percentage MAP reduction were similar between groups. Awakening time was 5.98 ± 1.02 vs. 6.42 ± 0.84 min ( P = 0.020); the difference was 0.44 min. Other documented adverse reactions consisted of dizziness (0 vs. 6 patients). Bradycardia and hypoxemia events were infrequent. Adjusted results were exploratory because of the limited event counts. Conclusion In this small retrospective comparison, adjunctive dexmedetomidine was associated with fewer recorded MAP reductions of at least 20% and rescue interventions, although mean hemodynamic measures did not differ materially. Awakening time differed modestly, and infrequent adverse events preclude firm safety conclusions. Larger studies with standardized monitoring and prespecified endpoints are needed.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fmed.2026.1907232
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Low-dose dexmedetomidine adjunct to ciprofol for gastrointestinal endoscopy: a retrospective study of relative MAP reduction and rescue interventions

Yang Li
Frontiers in Medicine
Anesthesia and Sedative Agents
article

Low-dose dexmedetomidine adjunct to ciprofol for gastrointestinal endoscopy: a retrospective study of relative MAP reduction and rescue interventions

Yang Li
article en

Abstract

Objective To examine the association of low-dose dexmedetomidine (0.3 μg/kg) added to ciprofol sedation with a patient-level mean arterial pressure (MAP) reduction of at least 20% from baseline, recorded rescue interventions, and early recovery during gastrointestinal endoscopy. Methods This single-center, retrospective, non-randomized comparative study included 100 adults (dexmedetomidine–ciprofol, n = 50; ciprofol alone, n = 50). No upper age limit was applied. In the adjunctive group, dexmedetomidine 0.3 μg/kg was administered intravenously before ciprofol; both groups received ciprofol titrated to clinical response. The primary outcome was an individual MAP decrease of at least 20% from the pre-sedation baseline, defined in the retrospective analysis plan before patient-level outcome derivation and between-group comparisons. Secondary outcomes included recorded rescue intervention, ciprofol dose, awakening time, intraoperative cardiorespiratory measures, bradycardia, hypoxemia, and other documented adverse reactions. Exploratory adjusted analyses supplemented unadjusted comparisons. Results The incidence of a MAP reduction of at least 20% was 16.0% vs. 36.0% [8/50 vs. 18/50; odds ratio [OR] 0.34, 95% confidence interval [CI]: 0.13–0.88; P = 0.039] in the dexmedetomidine-ciprofol and ciprofol-only groups, respectively. Recorded rescue interventions occurred in 20.0% vs. 40.0% (10/50 vs. 20/50; OR: 0.38, 95% CI: 0.15–0.92; P = 0.049). Mean lowest intraoperative MAP and mean percentage MAP reduction were similar between groups. Awakening time was 5.98 ± 1.02 vs. 6.42 ± 0.84 min ( P = 0.020); the difference was 0.44 min. Other documented adverse reactions consisted of dizziness (0 vs. 6 patients). Bradycardia and hypoxemia events were infrequent. Adjusted results were exploratory because of the limited event counts. Conclusion In this small retrospective comparison, adjunctive dexmedetomidine was associated with fewer recorded MAP reductions of at least 20% and rescue interventions, although mean hemodynamic measures did not differ materially. Awakening time differed modestly, and infrequent adverse events preclude firm safety conclusions. Larger studies with standardized monitoring and prespecified endpoints are needed.

Frontiers in MedicineVol. 13
Hubei University of Medicine (CN)
Good health and well-being
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon